Intratype variations of HPV 31 and 58 in Italian women with abnormal cervical cytology

Journal of Medical Virology

Volumn 83, Issue 10, 2011, Pages 1752-1761

  Cento, Valeria ^a   Rahmatalla, Noor ^a   Ciccozzi, Massimo ^b   Perno, Carlo Federico ^a,c   Ciotti, Marco ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Cervical lesions; HPV 31; HPV 58; HPV intratype variation

Indexed keywords

NEUTRALIZING ANTIBODY;

ADULT; ARTICLE; BINDING SITE; DISEASE COURSE; FEMALE; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 58; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHYLOGENETIC TREE; PROMOTER REGION; UTERINE CERVIX CYTOLOGY; VIRUS MUTATION; VIRUS TRANSCRIPTION;

ADULT; ALPHAPAPILLOMAVIRUS; AMINO ACID SEQUENCE; BASE SEQUENCE; CAPSID PROTEINS; CERVIX UTERI; DNA, VIRAL; FEMALE; GENETIC VARIATION; HUMAN PAPILLOMAVIRUS 31; HUMANS; ITALY; MOLECULAR SEQUENCE DATA; MUTATION; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; VAGINAL SMEARS;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 80051594192     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22201     Document Type: Article

References (43)

1. Bernard HU, Burk RD, Chen Z, van DK, Hausen H, de Villiers EM. 2010. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401: 70-79.
2. Berumen J, Ordoñez RM, Lazcano E, Salmeron J, Galvan SC, Estrada RA, Yunes E, Garcia-Carranca A, Gonzalez-Lira G, Madrigal-de la Campa A. 2001. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: A case-control study. J Natl Cancer Inst 93: 1325-1330.
3. Bishop B, Dasgupta J, Klein M, Garcea RL, Christensen ND, Zhao R, Chen XS. 2007. Crystal structures of four types of human papillomavirus L1 capsid proteins: Understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem 282: 31803-31811.
4. Bontkes HJ, van DM, de Gruijl TD, Duggan-Keen MF, Walboomers JM, Stukart MJ, Verheijen RH, Helmerhorst TJ, Meijer CJ, Scheper RJ, Stevens FR, Dyer PA, Sinnott P, Stern PL. 1998. HPV 16 infection and progression of cervical intra-epithelial neoplasia: Analysis of HLA polymorphism and HPV 16 E6 sequence variants. Int J Cancer 78: 166-171.
5. Burk RD, Terai M, Gravitt PE, Brinton LA, Kurman RJ, Barnes WA, Greenberg MD, Hadjimichael OC, Fu L, McGowan L, Mortel R, Schwartz PE, Hildesheim A. 2003. Distribution of human papillomavirus types 16 and 18 variants in squamous cellcarcinomas and adenocarcinomas of the cervix. Cancer Res 63: 7215-7220.
6. Calleja-Macias IE, Villa LL, Prado JC, Kalantari M, Allan B, Williamson AL, Chung LP, Collins RJ, Zuna RE, Dunn ST, Chu TY, Cubie HA, Cuschieri K, von Knebel-Doeberitz M, Martins CR, Sanchez GI, Bosch FX, Munoz N, Bernard HU. 2005. Worldwide genomic diversity of the high-risk human papillomavirus types 31, 35 52, and 58, four close relatives of human papillomavirus type 16. J Virol 79: 13630-13640.
7. Chan PK, Lam CW, Cheung TH, Li WW, Lo KW, Chan MY, Cheung JL, Cheng AF. 2002. Association of human papillomavirus type 58 variant with the risk of cervical cancer. J Natl Cancer Inst 94: 1249-1253.
8. Chang YJ, Chen HC, Lee BH, You SL, Lin CY, Pan MH, Chou YC, Hsieh CY, Chen YM, Cheng YJ, Chen CJ. CBCSPHPV Study Group. 2010. Unique variants of human papillomavirus genotypes 52 and 58 and risk of cervical neoplasia. Int J Cancer 129: 965-973.
9. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC. 2000. Structure of smallvirus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 5: 557-567.
10. de Boer MA, Peters LA, Aziz MF, Siregar B, Cornain S, Vrede MA, Jordanova ES, Fleuren GJ. 2005. Human papillomavirus type 18 variants: Histopathology and E6/E7 polymorphisms in three countries. Int J Cancer 114: 422-425.
11. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. 2004. Classification of papillomaviruses. Virology 324: 17-27.
12. Gagnon S, Hankins C, Tremblay C, Pourreaux K, Forest P, Rouah F, Coutlée F. 2005. Polymorphism of human papillomavirus type 31 isolates infecting the genital tract of HIV-seropositive and HIV-seronegative women at risk for HIV infection. J Med Virol 75: 213-221.
13. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GWK, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA. 2007. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356: 1928-1943.
14. Hall TA. 1999. Bioedit: A user-friendly biological sequence alignment, editor and analysis program for Windows 95/98 NT. Nucl Acids Symp Ser 41: 95-98.
15. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G. 2004. Efficacy of a bivalent L1 virus-like particle vaccine inprevention of infection with human papillomavirus types 16and 18 in young women: A randomised controlled trial. Lancet 364: 1757-1765.
16. Hecht JL, Kadish AS, Jiang G, Burk RD. 1995. Genetic characterization of the human papillomavirus (HPV) 18 E2 gene in clinical specimens suggests the presence of a subtype with decreased oncogenic potential. Int J Cancer 60: 369-376. .
17. Hu X, Guo Z, Tianyun P, Ponten F, Wilander E, Andersson S, Pontén J. 1999. HPV typing and HPV16 E6-sequence variations in synchronous lesions of cervical squamous-cell carcinoma from Swedish patients. Int J Cancer 83: 34-37.
18. Hubert WG. 2005. Variant upstream regulatory region sequences differentially regulate human papillomavirus type 16 DNA replication throughout the viral life cycle. J Virol 79: 5914-5922.
19. Kammer C, Tommasino M, Syrjanen S, Delius H, Hebling U, Warthorst U, Pfister H, Zehbe I. 2002. Variants of the long control region and the E6 oncogene in European human papillomavirus type 16 isolates: Implications for cervical disease. Br J Cancer 86: 269-273.
20. Kel AE, Goessling E, Reuter I, Cheremushkin E, Kel-Margoulis OV, Wingender E. 2003. MATCH(TM): A tool for searching transcription factor binding sites in DNA sequences. Nucleic Acids Res 31: 3576-3579.
21. Lee K, Magalhaes I, Clavel C, Briolat J, Birembaut P, Tommasino M, Zehbe I. 2008. Human papillomavirus 16 E6, L1, L2 and E2 gene variants in cervical lesion progression. Virus Res 131: 106-110.
22. Liu X, Clements A, Zhao K, Marmorstein R. 2006. Structure of the human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J Biol Chem 281: 578-586.
23. Londesborough P, Ho L, Terry G, Cuzick J, Wheeler C, Singer A. 1996. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 69: 364-368.
24. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wollnsky SM. 1989. Use of polymerase chain reaction for the detection of genital human papillomaviruses. Cancer Cells 7: 209-214.
25. Munoz N, Bosch FX, de SS, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527.
26. Nindl I, Rindfleisch K, Lotz B, Schneider A, Durst M. 1999. Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer. Int J Cancer 82: 203-207.
27. Nominé Y, Masson M, Charbonnier S, Zanier K, Ristriani T, Deryckère F, Sibler AP, Desplancq D, Atkinson RA, Weiss E, Orfanoudakis G, Kieffer B, Travé G. 2006. Structural and functional analysis of E6 oncoprotein: Insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol Cell 21: 665-678.
28. Parkin DM. 2001. Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543.
29. Pastrana DV, Vass WC, Lowy DR, Schiller JT. 2001. NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology 279: 361-369.
30. Quint KD, de Koning MN, van Doorn LJ, Quint WG, Pirog EC. 2010. HPV genotyping and HPV16 variant analysis in glandular and squamous neoplastic lesions of the uterine cervix. Gynecol Oncol 117: 297-301.
31. Raiol T, Wyant PS, de Amorim RM, Cerqueira DM, Milanezi NG, Brigido MM, Sichero L, Martins CR. 2009. Genetic variability and phylogeny of the high-risk HPV-31, -33, -35, -52, and -58 in Central Brazil. J Med Virol 81: 685-692.
32. Schiffman M, Rodriguez AC, Chen Z, Wacholder S, Herrero R, Hildesheim A, Desalle R, Befano B, Yu K, Safaeian M, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Solomon D, Castle PE, Burk RD. 2010. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res 70: 3159-3169.
33. Sichero L, Ferreira S, Trottier H, Duarte-Franco E, Ferenczy A, Franco EL, Villa LL. 2007. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer 120: 1763-1768.
34. Swofford DL, Sullivan J. 2003. Phylogeny inference based on parsimony and other methods with PAUP*. In: Salemi M, Vandamme AM, editors. The phylogenetic handbook-A practicalapproach to DNA and protein phylogeny. New York: Cambridge University Press Inc., p 160.
35. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol [Epub ahead of print].
36. Tornesello ML, Losito S, Benincasa G, Fulciniti F, Botti G, Greggi S, Buonaguro L, Buonaguro FM. 2011. Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix. Gynecol Oncol 121: 32-42.
37. Villa LL, Sichero L, Rahal P, Caballero O, Ferenczy A, Rohan T, Franco EL. 2000. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol 81: 2959-2968.
38. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19.
39. Xi LF, Koutsky LA, Castle PE, Edelstein ZR, Hulbert A, Schiffman M, Kiviat NB. 2010. Human papillomavirus type 16 variants in paired enrollment and follow-up cervicalsamples: Implications for a proper understanding of type-specific persistentinfections. J Infect Dis 202: 1667-1670.
40. Xin CY, Matsumoto K, Yoshikawa H, Yasugi T, Onda T, Nakagawa S, Yamada M, Nozawa S, Sekiya S, Hirai Y, Shiromizu K, Fujii T, Taketani Y. 2001. Analysis of E6 variants of human papillomavirus type 33, 52 and 58 in Japanese women with cervical intraepithelial neoplasia/cervical cancer in relation to their oncogenic potential. Cancer Lett 170: 19-24.
41. Yamada T, Wheeler CM, Halpern AL, Stewart AC, Hildesheim A, Jenison SA. 1995. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol 69: 7743-7753.
42. Yang R, Wheeler CM, Chen X, Uematsu S, Takeda K, Akira S, Pastrana DV, Viscidi RP, Roden RB. 2005. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. J Virol 79: 6741-6750.
43. Zehbe I, Voglino G, Wilander E, Delius H, Marongiu A, Edler L, Klimek F, Andersson S, Tommasino M. 2001. p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res 61: 608-611.